Tobias Jagomast
Overview
Explore the profile of Tobias Jagomast including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jagomast T, Finck J, Tangemann-Munstedt I, Auth K, Dromann D, Franzen K
Online J Public Health Inform
. 2024 Dec;
16:e57718.
PMID: 39626237
Background: Smoking is a modifiable risk factor for SARS-CoV-2 infection. Evidence of smoking behavior during the pandemic is ambiguous. Most investigations report an increase in smoking. In this context, Google...
2.
Jagomast T, Mohr T, Axt P, Mortensen K, Brinkmann F, Weckmann M, et al.
J Funct Morphol Kinesiol
. 2023 Jul;
8(3).
PMID: 37489314
Cardiovascular health at a young age has implications for preventing cardiovascular disease, and it is associated with improved physical and cognitive performance during the aging process. Sports are well known...
3.
Kuempers C, Jagomast T, Paulsen F, Heidel C, Bohnet S, Schierholz S, et al.
Histol Histopathol
. 2023 Jul;
39(4):437-446.
PMID: 37409491
Background: Despite promising results of targeted therapy approaches, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death. Tripartite motif containing 11 (TRIM11) is part of the TRIM...
4.
VON Bernuth A, Ribbat-Idel J, Klapper L, Jagomast T, Rades D, Leichtle A, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982215
Patients with head and neck squamous cell carcinoma (HNSCC) continue to have a rather poor prognosis. Treatment-related comorbidities have negative impacts on their quality of life. TRIM21 is a cytosolic...
5.
Kuempers C, Jagomast T, Heidel C, Paulsen F, Bohnet S, Schierholz S, et al.
Front Oncol
. 2022 Oct;
12:927140.
PMID: 36212402
Aim: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death globally despite promising progress of personalized therapy approaches. Cyclin-dependent kinase 7 (CDK7) is a kinase involved in...
6.
Klapper L, Idel C, Kuppler P, Jagomast T, VON Bernuth A, Bruchhage K, et al.
J Pers Med
. 2022 Jun;
12(6).
PMID: 35743773
Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most common cancers in humans worldwide and have a rather poor prognosis. TRIM24 has various intracellular functions and was...
7.
Bottner J, Ribbat-Idel J, Klapper L, Jagomast T, Lemster A, Perner S, et al.
Int J Mol Sci
. 2022 May;
23(9).
PMID: 35563463
Head and neck squamous cell carcinomas (HNSCC) are among the most common cancers worldwide and are associated with a poor prognosis for patients. Among HNSCC, those originating in the hypopharynx...
8.
Jagomast T, Idel C, Klapper L, Kuppler P, Offermann A, Dreyer E, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158760
HNSCC is the sixth most common cancer worldwide and the prognosis is still poor. Here, we investigated the prognostic implications of CDK7 and pMED1. Both proteins affect transcription, and their...
9.
Kuempers C, Jagomast T, Krupar R, Paulsen F, Heidel C, Ribbat-Idel J, et al.
Front Med (Lausanne)
. 2021 Oct;
8:734901.
PMID: 34692726
Rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate directed against Delta-like protein 3 (DLL3), is under development for patients with small cell lung cancer (SCLC). DLL3 is expressed on the majority of...